Theratechnologies Inc (THTX) - News Archive

In recent developments, Future Pak, LLC has taken significant steps towards acquiring Theratechnologies Inc. (NASDAQ: THTX) by submitting two formal acquisition proposals since January 2023. The latest proposal offers a...

Theratechnologies Resumes Distribution of EGRIFTA SV After FDA Clearance February 13, 2025Montreal Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a leading specialty biopharmaceutical company, proudly announced today...

In an era where the healthcare landscape is constantly evolving, Theratechnologies Inc. finds itself at a critical juncture, grappling with challenges and opportunities that could shape its future. The Montreal-based bi...

: Theratechnologies has released preliminary tolerability and efficacy data from a Phase 1b, dose-ranging trial of Sudocetaxel Zendusortide, a therapeutic agent designed for patients with advanced ovarian cancer. The tr...

Biopharmaceutical Innovation and Digital Security: A Dual Frontiers Approach As the biopharmaceutical landscape continues to evolve, companies like Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) are at the forefront of...

MONTREAL, Dec. 10, 2024 — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies, announced today that the United States F...

Exploration of PROMISE-US Trial Design and Baseline Characteristics in the Study of Ibalizumab for HIV Patients with Multidrug Resistance The global struggle against HIV continues to challenge the scientific and medical...

Theratechnologies Showcases Versatility of SORT1+ Technology in Preclinical Data Presentation Theratechnologies, a biopharmaceutical company dedicated to the development of innovative therapies, recently presented precl...

MONTREAL, March 28, 2024 - Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies, is poised to make a significant impact in...

Leading the Charge in Cybersecurity: Embracing Outsourced Solutions to Navigate an Evolving Digital LandscapeNashville, Tenn., March 22, 2024 - In today s fast-paced and ever-evolving cyber landscape, organizations worl...

Theratechnologies Expands Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide for Advanced Ovarian CancerMONTREAL, March 21, 2024 - Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical compa...

In a recent development, biopharmaceutical company Theratechnologies Inc. has received a refusal to file letter (RTF) from the United States Food and Drug Administration (FDA) regarding the company s supplemental Biolog...

The receipt of the CRL from the FDA is a significant step in the journey of tesamorelin s F8 formulation, which has been in a meticulous process of research and development by the company’s specialized team. The CRL is...

Theratechnologies Inc., a biopharmaceutical company specializing in the development and commercialization of innovative therapies, recently received an update from the U.S. Food and Drug Administration (FDA) concerning...